国药现代：磷酸西格列汀获得化学原料药上市申请批准通知书

Core Viewpoint - The announcement by China National Pharmaceutical Group Modern (国药现代) regarding the approval of the active pharmaceutical ingredient, phosphate sitagliptin, indicates a significant advancement in the company's product offerings in the diabetes treatment sector [1] Company Summary - China National Pharmaceutical Group Modern's wholly-owned subsidiary, China National Pharmaceutical Wichida, has received the approval notice from the National Medical Products Administration for the marketing application of phosphate sitagliptin [1] - Phosphate sitagliptin is classified as a DPP-4 inhibitor, primarily used in clinical settings to improve blood sugar control in patients with type 2 diabetes [1]